Navigation Links
Emerging Global Leader in Emergency Thermotherapy for Traumatic Brain Injury Expands US Operations to Site on the Campus of New York Medical College

Valhalla, NY (PRWEB) July 30, 2013

Thermopraxis, LLC, ( an early stage, innovative medical device company with emergency treatment for concussions/traumatic brain injury (TBI) and spinal cord injury is proud to announce that it will continue expansion of its US operations and base its new headquarters at New York Medical College’s (NYMC) Valhalla campus in Westchester. Thermopraxis continues to advance a highly collaborative, creative “praxis” (meaning the act of applying, or practicing ideas or concepts) designed to engage their expanding network of entrepreneurs, researchers, investors, and partners, who are working together to make meaningful change in health through the development of therapies for traumatic or hypoxic-ischemic brain and spinal cord injuries, and other systemic injuries (contusions) using the recognized therapeutic effects of hypothermia or cooling.

“We are excited to retain our headquarters in New York and leverage the abundant resources in the growing cluster in and around the Hudson Valley,” stated Renato Rozental, MD, PhD, CEO and Chief Scientific Officer of Thermopraxis. “We are equally excited about our ongoing developments with Thermocrown, the first device that will enable emergency thermotherapy care out in the field to confer brain protection post-traumatic injury. At current, there are no other devices or treatments available anywhere in the world which promise similar efficacy or that can be activated under pre-clinical conditions, such as the battlefield or during catastrophic events. The Hudson Valley will be home to one of the most important emerging technology of this generation as we make preparation to begin production of Thermocrown for our soldiers and ultimately to benefit society.”

"Landing an exciting, new firm like Thermopraxis transforms New York Medical College's Business Incubator from a concept-on-a-blackboard to a job-creating bricks-mortar-and-lab coats reality. I am proud I was an early, ardent supporter of the effort to launch a biotechnology incubator for entrepreneurs and startups that will develop cutting-edge drugs and treatments that can make Westchester a national center for excellence in the field of biotechnology" said Senator Charles Schumer (D, NY).

“Timing is everything in life,” said Anthony L. Finley, LLB (Hons.), President of Thermopraxis. “This move comes at a critical point in our ongoing operations, as we continue to accelerate the advancement of our non-invasive acute treatment for TBI that not only protects against neuronal injury but also promises to ameliorate the long-term prospects for victims of TBI. We are looking forward to the time in the very near future when military and sports helmets of all types have our device installed, and ambulances worldwide will carry our device ready to treat victims of head and spinal cord injuries literally within minutes and sometimes seconds after a blow. Use of our device is the only safe and effective way of providing the patient with neuroprotection before he or she reaches the hospital, yet it is simple enough to be activated by anyone without any special training. With our commercial partners Schutt Sports and a major specialty gas distributor company, we are striving to end the concussion crisis, save many lives and improve the outcome for millions more worldwide.”

“I would like to congratulate Thermopraxis on their selection of the Incubator at New York Medical College’s (NYMC) Valhalla campus for their headquarters,” said Kirsten Gillibrand, United States Senator, who helped launch the BioHud Valley Initiative in 2010 with the Hudson Valley Economic Development Corporation. “With investments like Thermopraxis’, BioHud is delivering on its promise to leverage the regions world-class universities to attract more businesses, strengthening manufacturing and creating new jobs throughout the Hudson Valley.”

“New York Medical College welcomes a pioneering company like Thermopraxis to our campus as our first prospective incubator tenant,” said Robert W. Amler, MD, NYMC’s Dean of the School of Health Sciences and Practice and Vice President of Government Affairs. “This is a promising new venture that, if successful, could transform our approach to traumatic brain injuries in a very meaningful way.”

“With Thermopraxis' announcement that it will establish its headquarters at NYMC in Valhalla, we continue to add to our world-class ecosystem that is the NY BioHud Valley.” Larry Gottlieb, president of the Hudson Valley Economic Development Corporation, continued, “We’re creating this growth environment by facilitating networking discussions among biotech and medical device executives, moving innovative companies such as Thermopraxis into the Hudson Valley, and connecting firms to NYMC’s incredible resources. That’s how you build a successful biotech cluster.”

About Thermopraxis-Stratego Alliance
Thermopraxis, LLC was founded by partners Renato Rozental, MD, PhD, CEO and Chief Scientific Officer of the Company, and Anthony L. Finley, LLB (Hons.), President of the Company, to commercialize the company’s proprietary therapies for traumatic or hypoxic-ischemic brain and spinal cord injuries, and other systemic injuries (contusions) using the recognized therapeutic effects of hypothermia or cooling. Thermopraxis in New York operates in alliance with Stratego, its sister company in Rio de Janeiro, Brazil. Both companies are owned by the same principals and have the same goals, but the strategy of creating two companies, one based in the USA and the other in Brazil has enabled the Alliance to draw upon the benefits available for the advancement of technology offered in each country. Thermopraxis in collaboration with its Brazilian partner company Stratego will continue to translate academic research data into potential clinical benefits for these patients. The Thermopraxis/Stratego Alliance benefits from its unique capability of developing basic and clinical trials, carrying out Phase-I and bioequivalence studies involving healthy volunteers, as well as Phase IIA studies with patients in collaboration with Grupo DÓr, one of the largest and most complete private networks of diagnostic medicine and hospital assistance in Brazil. For more information, please visit

About New York Medical College
New York Medical College, a member of the Touro College and University System, is one of the nation’s largest private health sciences universities with more than 1,400 students and 850 residents and fellows and nearly 3,000 faculty members. The leading academic biomedical research institution between New York City and Albany, the university manages more than $34 million in research and other sponsored programs, notably in the areas of cardiovascular disease, cancer, kidney disease, the neurosciences and infectious diseases. If you are a member of the media and would like more information about New York Medical College or any of the subjects mentioned in our news releases, please contact the Office of Public Relations at (914) 594-4536.

About Hudson Valley Economic Development Corporation
Hudson Valley Economic Development Corporation represents seven counties in the Hudson Valley. This public-private partnership markets the region as a prime business location to corporate executives, site selection consultants and real estate brokers. HVEDC launched the major branding and marketing effort for NY BioHud Valley. For more information on Hudson Valley Economic Development Corporation or to review available business sites, visit or call 845-220-2244.


Contact: Hudson Valley Economic Development/Axon Communications, Evita Sanchez (914) 434 0418,
esanchez(at)axon-com(dot)com, Josephine Di Laura (917) 940-7563, jdilaura(at)axon-com(dot)com

Read the full story at

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Next Generation Sequencing: Emerging Clinical Applications and Global Markets
2. Surveyed U.S. Payers Are Significantly More Likely To Reimburse Biosimilars Developed By Multinational Manufacturers Compared With Those Developed By Regional Emerging Market Players
3. PrimeraDx Featured in the Goldman Sachs Healthcare Research Teams GS Emerging Healthcare Series
4. Early Stage Drug Delivery Technologies: 62 Profiles of Start-ups and Emerging Companies
5. Viropro and Oncobiologics Sign Emerging Markets Biosimilars Deal
6. Research and Markets: Biologics in the Emerging Markets: Ripe for Realization of the Commercial Potential - But Hurdles Still to Overcome
7. New Product Launch: Are your Strategies for Emerging Healthcare and Life Sciences Markets Innovative and Structured?
8. Webinar to Discuss Biosimilar Regulatory Guidelines in India and Emerging Markets
9. Intellitech Announces New Micro Pump Promotes Rapid Growth of Emerging BioTech
10. France & Germany Blood Banking Market: Innovative Technologies and Emerging Business Opportunities in New Research Report at
11. Parthenon Identifies Emerging Opportunities in Targeted Payload Cancer Therapeutics
Post Your Comments:
(Date:11/24/2015)...  Clintrax Global, Inc., a worldwide provider of clinical research services ... that the company has set a new quarterly earnings record in ... growth posted for Q3 of 2014 to Q3 of 2015.   ... , with the establishment of an Asia-Pacific ... United Kingdom and Mexico , ...
(Date:11/24/2015)... (PRWEB) , ... November 24, 2015 , ... This fall, ... at competitive events in five states to develop and pitch their BIG ideas to ... from each state are competing for votes to win the title of SAP's Teen ...
(Date:11/24/2015)... 24, 2015 SHPG ) announced today that ... Piper Jaffray 27 th Annual Healthcare Conference in ... at 8:30 a.m. EST (1:30 p.m. GMT). --> SHPG ... will participate in the Piper Jaffray 27 th Annual Healthcare ... Tuesday, December 1, 2015, at 8:30 a.m. EST (1:30 p.m. GMT). ...
(Date:11/24/2015)... -- Tikcro Technologies Ltd. (OTCQB: TIKRF) today announced that its Annual General Meeting ... Israel time, at the law offices of ... th Floor, Tel Aviv, Israel . ... Izhak Tamir to the Board of Directors; , election of ... approval of an amendment to certain terms of options granted to our ...
Breaking Biology Technology:
(Date:11/2/2015)... 2015  SRI International has been awarded a contract ... services to the National Cancer Institute (NCI) PREVENT Cancer ... expertise, modern testing and support facilities, and analytical instrumentation ... toxicology studies to evaluate potential cancer prevention drugs. ... Cancer Drug Development Program is an NCI-supported pipeline to ...
(Date:10/29/2015)... JOLLA, Calif. , Oct. 29, 2015  The ... a new report titled, "DNA Synthesis and Biosecurity: Lessons ... well the Department of Health and Human Services guidance ... issued in 2010. --> ... but it also has the potential to pose unique ...
(Date:10/29/2015)... ARBOR, Mich. , Oct. 29, 2015 /PRNewswire/ ... Eurofins Genomics for U.S. distribution of its DNA ... DNA-seq kit and Rubicon,s new ThruPLEX Plasma-seq kit. ... to enable the preparation of NGS libraries for ... plasma for diagnostic and prognostic applications in cancer ...
Breaking Biology News(10 mins):